These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 29021281)

  • 1. Survival of BRCA2-Deficient Cells Is Promoted by
    Ding X; Philip S; Martin BK; Pang Y; Burkett S; Swing DA; Pamala C; Ritt DA; Zhou M; Morrison DK; Ji X; Sharan SK
    Genetics; 2017 Dec; 207(4):1335-1345. PubMed ID: 29021281
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
    Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
    [No Abstract]   [Full Text] [Related]  

  • 3. Appl1 and Appl2 are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts.
    Tan Y; Xin X; Coffey FJ; Wiest DL; Dong LQ; Testa JR
    J Cell Physiol; 2016 May; 231(5):1142-50. PubMed ID: 26445298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage.
    Biswas K; Philip S; Yadav A; Martin BK; Burkett S; Singh V; Babbar A; North SL; Chang S; Sharan SK
    Nat Commun; 2018 Feb; 9(1):537. PubMed ID: 29416040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional evaluation of five BRCA2 unclassified variants identified in a Sri Lankan cohort with inherited cancer syndromes using a mouse embryonic stem cell-based assay.
    Sirisena N; Biswas K; Sullivan T; Stauffer S; Cleveland L; Southon E; Dissanayake VHW; Sharan SK
    Breast Cancer Res; 2020 May; 22(1):43. PubMed ID: 32393398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mismatch repair protein MLH1 suppresses replicative stress in BRCA2-deficient breast tumors.
    Sengodan SK; Hu X; Peddibhotla V; Balamurugan K; Mitrophanov AY; McKennett L; Kharat SS; Sanawar R; Singh VK; Albaugh ME; Burkett SS; Zhao Y; Tran B; Malys T; Sterneck E; De S; Sharan SK
    J Clin Invest; 2024 Jan; 134(7):. PubMed ID: 38271119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
    Ding X; Ray Chaudhuri A; Callen E; Pang Y; Biswas K; Klarmann KD; Martin BK; Burkett S; Cleveland L; Stauffer S; Sullivan T; Dewan A; Marks H; Tubbs AT; Wong N; Buehler E; Akagi K; Martin SE; Keller JR; Nussenzweig A; Sharan SK
    Nat Commun; 2016 Aug; 7():12425. PubMed ID: 27498558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
    Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
    Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA2 and TP53 collaborate in tumorigenesis in zebrafish.
    Shive HR; West RR; Embree LJ; Golden CD; Hickstein DD
    PLoS One; 2014; 9(1):e87177. PubMed ID: 24489863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
    Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
    Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular cloning and characterization of mouse Gipc3.
    Saitoh T; Mine T; Katoh M
    Int J Mol Med; 2002 Mar; 9(3):251-6. PubMed ID: 11836631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation.
    Connor F; Bertwistle D; Mee PJ; Ross GM; Swift S; Grigorieva E; Tybulewicz VL; Ashworth A
    Nat Genet; 1997 Dec; 17(4):423-30. PubMed ID: 9398843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.
    Bell DW; Erban J; Sgroi DC; Haber DA
    Cancer Res; 2002 May; 62(10):2741-3. PubMed ID: 12019146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
    Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
    Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.
    Okada S; Tokunaga E; Kitao H; Akiyoshi S; Yamashita N; Saeki H; Oki E; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 May; 19(5):1499-507. PubMed ID: 22179631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular cloning and characterization of human GIPC3, a novel gene homologous to human GIPC1 and GIPC2.
    Saitoh T; Mine T; Katoh M
    Int J Oncol; 2002 Mar; 20(3):577-82. PubMed ID: 11836571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.
    Ingvarsson S; Agnarsson BA; Sigbjornsdottir BI; Kononen J; Kallioniemi OP; Barkardottir RB; Kovatich AJ; Schwarting R; Hauck WW; Huebner K; McCue PA
    Cancer Res; 1999 Jun; 59(11):2682-9. PubMed ID: 10363992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA2 minor transcript lacking exons 4-7 supports viability in mice and may account for survival of humans with a pathogenic biallelic mutation.
    Thirthagiri E; Klarmann KD; Shukla AK; Southon E; Biswas K; Martin BK; North SL; Magidson V; Burkett S; Haines DC; Noer K; Matthai R; Tessarollo L; Loncarek J; Keller JR; Sharan SK
    Hum Mol Genet; 2016 May; 25(10):1934-1945. PubMed ID: 26920070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of Heterozygosity in BRCA1 and BRCA2 Genes in Patients with Ovarian Cancer and Probability of Its Use for Clinical Classification of Variations.
    Kechin AA; Boyarskikh UA; Ermolenko NA; Tyulyandina AS; Lazareva DG; Avdalyan AM; Tyulyandin SA; Kushlinskii NE; Filipenko ML
    Bull Exp Biol Med; 2018 May; 165(1):94-100. PubMed ID: 29797126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.